Video

Genetic Testing Is Important for Both Patients and Family Members

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

Marshall - who is chief of the Division of Hematology/Oncology at MedStar Georgetown University Hospital, professor of medicine and oncology at the Lombardi Comprehensive Cancer Center at Georgetown University, and director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer — says that testing positive for MSI-H can have important treatment implications for the patient, and may signal to family members that they should be tested, too.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Related Content